220 related articles for article (PubMed ID: 38549180)
1. The pathology of X-linked adrenoleukodystrophy: tissue specific changes as a clue to pathophysiology.
Yska HAF; Engelen M; Bugiani M
Orphanet J Rare Dis; 2024 Mar; 19(1):138. PubMed ID: 38549180
[TBL] [Abstract][Full Text] [Related]
2. Metformin-induced mitochondrial function and ABCD2 up-regulation in X-linked adrenoleukodystrophy involves AMP-activated protein kinase.
Singh J; Olle B; Suhail H; Felicella MM; Giri S
J Neurochem; 2016 Jul; 138(1):86-100. PubMed ID: 26849413
[TBL] [Abstract][Full Text] [Related]
3. Spinal cord atrophy as a measure of severity of myelopathy in adrenoleukodystrophy.
van de Stadt SIW; van Ballegoij WJC; Labounek R; Huffnagel IC; Kemp S; Nestrasil I; Engelen M
J Inherit Metab Dis; 2020 Jul; 43(4):852-860. PubMed ID: 32077106
[TBL] [Abstract][Full Text] [Related]
4. Late onset neurological phenotype of the X-ALD gene inactivation in mice: a mouse model for adrenomyeloneuropathy.
Pujol A; Hindelang C; Callizot N; Bartsch U; Schachner M; Mandel JL
Hum Mol Genet; 2002 Mar; 11(5):499-505. PubMed ID: 11875044
[TBL] [Abstract][Full Text] [Related]
5. Pathophysiology of X-linked adrenoleukodystrophy.
Berger J; Forss-Petter S; Eichler FS
Biochimie; 2014 Mar; 98(100):135-42. PubMed ID: 24316281
[TBL] [Abstract][Full Text] [Related]
6. Endocrine dysfunction in adrenoleukodystrophy.
Engelen M; Kemp S; Eichler F
Handb Clin Neurol; 2021; 182():257-267. PubMed ID: 34266597
[TBL] [Abstract][Full Text] [Related]
7. Hematopoietic cell transplantation does not prevent myelopathy in X-linked adrenoleukodystrophy: a retrospective study.
van Geel BM; Poll-The BT; Verrips A; Boelens JJ; Kemp S; Engelen M
J Inherit Metab Dis; 2015 Mar; 38(2):359-61. PubMed ID: 25488625
[TBL] [Abstract][Full Text] [Related]
8. X-linked adrenoleukodystrophy and primary adrenal insufficiency.
Cappa M; Todisco T; Bizzarri C
Front Endocrinol (Lausanne); 2023; 14():1309053. PubMed ID: 38034003
[TBL] [Abstract][Full Text] [Related]
9. MRI and proton MRSI in women heterozygous for X-linked adrenoleukodystrophy.
Fatemi A; Barker PB; Uluğ AM; Nagae-Poetscher LM; Beauchamp NJ; Moser AB; Raymond GV; Moser HW; Naidu S
Neurology; 2003 Apr; 60(8):1301-7. PubMed ID: 12707433
[TBL] [Abstract][Full Text] [Related]
10. Lipid-induced endoplasmic reticulum stress in X-linked adrenoleukodystrophy.
van de Beek MC; Ofman R; Dijkstra I; Wijburg F; Engelen M; Wanders R; Kemp S
Biochim Biophys Acta Mol Basis Dis; 2017 Sep; 1863(9):2255-2265. PubMed ID: 28666219
[TBL] [Abstract][Full Text] [Related]
11. [X-linked adrenoleukodystrophy].
Aubourg P
Ann Endocrinol (Paris); 2007 Dec; 68(6):403-11. PubMed ID: 17532287
[TBL] [Abstract][Full Text] [Related]
12. Adult-onset cerebello-brainstem dominant form of X-linked adrenoleukodystrophy presenting as multiple system atrophy: case report and literature review.
Ogaki K; Koga S; Aoki N; Lin W; Suzuki K; Ross OA; Dickson DW
Neuropathology; 2016 Feb; 36(1):64-76. PubMed ID: 26227820
[TBL] [Abstract][Full Text] [Related]
13. C26:0-Carnitine Is a New Biomarker for X-Linked Adrenoleukodystrophy in Mice and Man.
van de Beek MC; Dijkstra IM; van Lenthe H; Ofman R; Goldhaber-Pasillas D; Schauer N; Schackmann M; Engelen-Lee JY; Vaz FM; Kulik W; Wanders RJ; Engelen M; Kemp S
PLoS One; 2016; 11(4):e0154597. PubMed ID: 27124591
[TBL] [Abstract][Full Text] [Related]
14. Lack of adrenoleukodystrophy protein enhances oligodendrocyte disturbance and microglia activation in mice with combined Abcd1/Mag deficiency.
Dumser M; Bauer J; Lassmann H; Berger J; Forss-Petter S
Acta Neuropathol; 2007 Dec; 114(6):573-86. PubMed ID: 17828604
[TBL] [Abstract][Full Text] [Related]
15. Two Single Nucleotide Deletions in the
Dohr KA; Tokic S; Gastager-Ehgartner M; Stojakovic T; Dumic M; Plecko B; Dumic KK
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36983033
[TBL] [Abstract][Full Text] [Related]
16. Early oxidative damage underlying neurodegeneration in X-adrenoleukodystrophy.
Fourcade S; López-Erauskin J; Galino J; Duval C; Naudi A; Jove M; Kemp S; Villarroya F; Ferrer I; Pamplona R; Portero-Otin M; Pujol A
Hum Mol Genet; 2008 Jun; 17(12):1762-73. PubMed ID: 18344354
[TBL] [Abstract][Full Text] [Related]
17. Management of adrenoleukodystrophy: From pre-clinical studies to the development of new therapies.
Ma CY; Li C; Zhou X; Zhang Z; Jiang H; Liu H; Chen HJ; Tse HF; Liao C; Lian Q
Biomed Pharmacother; 2021 Nov; 143():112214. PubMed ID: 34560537
[TBL] [Abstract][Full Text] [Related]
18. X-linked adrenoleukodystrophy in a chimpanzee due to an ABCD1 mutation reported in multiple unrelated humans.
Curiel J; Steinberg SJ; Bright S; Snowden A; Moser AB; Eichler F; Dubbs HA; Hacia JG; Ely JJ; Bezner J; Gean A; Vanderver A
Mol Genet Metab; 2017 Nov; 122(3):130-133. PubMed ID: 28919002
[TBL] [Abstract][Full Text] [Related]
19. Antioxidants halt axonal degeneration in a mouse model of X-adrenoleukodystrophy.
López-Erauskin J; Fourcade S; Galino J; Ruiz M; Schlüter A; Naudi A; Jove M; Portero-Otin M; Pamplona R; Ferrer I; Pujol A
Ann Neurol; 2011 Jul; 70(1):84-92. PubMed ID: 21786300
[TBL] [Abstract][Full Text] [Related]
20. Novel
Cho YK; Lee SY; Kim SW
Endocrinol Metab (Seoul); 2020 Mar; 35(1):188-191. PubMed ID: 32207279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
